Bank Julius Baer & Co. Ltd Zurich Buys New Position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)


Share on StockTwits

Bank Julius Baer & Co. Ltd Zurich bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the fourth quarter, Holdings Channel.com reports. The fund bought 17,974 shares of the company’s stock, valued at approximately $55,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CYCN. NorthRock Partners LLC purchased a new stake in Cyclerion Therapeutics in the fourth quarter valued at approximately $31,000. Renaissance Technologies LLC purchased a new stake in Cyclerion Therapeutics in the fourth quarter valued at approximately $55,000. Virtu Financial LLC purchased a new stake in Cyclerion Therapeutics in the third quarter valued at approximately $63,000. GSA Capital Partners LLP purchased a new stake in Cyclerion Therapeutics in the fourth quarter valued at approximately $71,000. Finally, Rhumbline Advisers raised its stake in Cyclerion Therapeutics by 15.8% in the fourth quarter. Rhumbline Advisers now owns 34,065 shares of the company’s stock valued at $104,000 after purchasing an additional 4,652 shares in the last quarter. 68.17% of the stock is currently owned by institutional investors and hedge funds.

CYCN stock opened at $2.88 on Thursday. The company has a market capitalization of $98.08 million, a PE ratio of -0.97 and a beta of 2.20. Cyclerion Therapeutics, Inc. has a one year low of $2.18 and a one year high of $8.96. The company’s 50 day moving average price is $3.79 and its two-hundred day moving average price is $3.76.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings results on Thursday, February 25th. The company reported ($0.55) EPS for the quarter. The business had revenue of $0.13 million for the quarter. Cyclerion Therapeutics had a negative return on equity of 105.55% and a negative net margin of 2,322.42%.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction.

Featured Article: Why Invest in Dividend Achievers?

Want to see what other hedge funds are holding CYCN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cyclerion Therapeutics, Inc. (NASDAQ:CYCN).

Institutional Ownership by Quarter for Cyclerion Therapeutics (NASDAQ:CYCN)

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.